MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

January 3, 2023

https://www.globenewswire.com/news-release/2023/01/03/2582484/0/en/MaxCyte-Signs-Strategic-Platform-License-with-Catamaran-Bio-to-Support-its-CAR-NK-Cell-Therapy-Programs.html

ROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq:MXCT; LSE:MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc., a biotechnology company developing novel, off the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat a broad range of cancers, with a primary focus on solid tumors.

Read more at globenewswire.com

Related news for (MXCT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.